Silexion advances SIL204 into Phase 2/3 trial, reports Q2 2026 results
Silexion initiated its Phase 2/3 pancreatic cancer trial in Israel after German regulatory clearance, while cash fell to $2.2 million and it closed a $2.5 million offering.
Silexion Therapeutics Corp reported second quarter 2026 results and a business update on August 14, 2026, tied to progress on its lead siRNA candidate SIL204 in locally advanced pancreatic cancer. During the second quarter and subsequent to quarter end, Silexion advanced SIL204 into active Phase 2/3 clinical evaluation in locally advanced pancreatic cancer.1
On the regulatory front, the company submitted its Clinical Trial Application to Germany's BfArM in April 2026, with Germany serving as Reference Member State for the European program, and received CTA approval from BfArM in June 2026, along with a positive opinion from the Ethics Committee of the North Rhine Medical Association, adding Germany to the previously received approval from the Israeli Ministry of Health.1 On July 29, 2026, Silexion initiated the Phase 2/3 trial at Tel Aviv Sourasky Medical Center, clearing the site to begin patient screening, with first patient dosing anticipated to follow.1 Additional Israeli and German trial sites are progressing through activation and are expected to join the program in the coming months.1
The company also expanded preclinical immuno-oncology data. In August 2026, it reported statistically significant upregulation of FAS (CD95) and downregulation of HLA-G across three distinct KRAS mutations, which together with earlier findings support what the company calls a coordinated immune-sensitization signature across three immune pathways observed across four KRAS mutations (G12D, G12V, G12C, and G12R), reinforcing the rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitors.1
On finances, cash and cash equivalents were approximately $2.2 million as of June 30, 2026, compared to approximately $6.0 million as of December 31, 2025.1 On August 13, 2026, the company closed a registered public offering with aggregate gross proceeds of approximately $2.5 million and net proceeds of approximately $2.1 million.1 The company estimates its shareholders' equity as of June 30, 2026, adjusted for subsequent transactions, is approximately $3.2 million, above Nasdaq's $2.5 million minimum, and it believes it has restored compliance with that listing requirement.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.